| Adenocarcinoma |
| Not yet recruiting | 4 | 1500 | RoW | Vitamin D3 | Third Affiliated Hospital, Sun Yat-Sen University | Hepatitis B, Carcinoma, Hepatocellular | 06/16 | 12/26 | | |
NCT02435953: TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma |
|
|
| Recruiting | 4 | 1 | RoW | TACE, RFA | Ming Zhao | Hepatocellular Carcinoma, Chemoembolization, Therapeutic, Ablation Techniques, RFA | 05/23 | | | |
| Not yet recruiting | 4 | 340 | RoW | laparoscopic surgery(LS), RFA | Sun Yat-sen University, Second Military Medical University | Hepatocellular Carcinoma | 12/26 | 12/26 | | |
| Active, not recruiting | 3 | 2205 | Europe, Canada, RoW | Prostatectomy, Conventionally Fractionated Prostate Radiotherapy, Prostate SBRT | Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Sutton, Surrey, UK | Prostate Cancer | 12/25 | 12/27 | | |
NCT02715492: Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma. |
|
|
| Not yet recruiting | 3 | 40 | RoW | LMWH, Enoxaparin, TACE | Sherief Abd-Elsalam | HCC | 12/22 | 12/22 | | |
BALLAD, NCT02502370: Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 100 | Europe | observation alone, LV5FU2, FOLFOX | Centre Hospitalier Universitaire Dijon | Small Bowel Adenocarcinoma, Adjuvant Chemotherapy for SBA | 09/23 | | | |
SANO, NCT02705651: Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment |
|
|
| Not yet recruiting | 3 | 180 | NA | Somatostatin-Analog | Medical University of Vienna | Pancreatic Neuroendocrine Tumors in MEN1 | 10/23 | 10/24 | | |
NCT02646137: Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma |
|
|
| Recruiting | 3 | 50 | RoW | Transarterial chemoembolization (TACE), Transarterial chemoembolization, Radiofrequency ablation combined with TACE, Microwave ablation combined with TACE | Sherief Abd-Elsalam, Tanta University | Liver Cancer | 12/23 | 12/23 | | |
NCT02482454: Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma |
|
|
| Active, not recruiting | 3 | 50 | RoW | Radiofrequency ablation, RFA, Cytokine-induced killer cells, CIK | The First People's Hospital of Changzhou | Cholangiocarcinoma | 07/30 | 07/33 | | |
SHPD002, NCT02221999: Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients |
|
|
| Active, not recruiting | 2/3 | 250 | RoW | Paclitaxel, Taxol, Cisplatin, Gonadotropin-releasing hormone agonist, Letrozole | RenJi Hospital | Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Ductal Breast Cancer, Inflammatory Breast Cancer | 01/19 | 01/29 | | |
Esostrate, NCT02551458: Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy |
|
|
| Terminated | 2/3 | 188 | Europe | Systematic surgery, Surveillance and rescue surgery in cases of resectable loco-regional recurrence | Centre Hospitalier Universitaire Dijon | Epidermoid Carcinoma or, Adenocarcinoma of the Thoracic Oesophagus or, Adenocarcinoma of the Oesogastric Junction (Siewert Type I or II), Stage cT2 N1-3 M0 or cT3-T4a N0 or N1-3 M0 | 03/23 | | | |
NCT00003915: Chemotherapy and Hormone Therapy in Treating Patients With Prostate Cancer |
|
|
| Active, not recruiting | 2 | 63 | US | bicalutamide, docetaxel, estramustine phosphate sodium, leuprolide acetate | University of Massachusetts, Worcester | Prostate Cancer | 02/18 | 02/18 | | |
NCT02755675 / 2015-005642-59: uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung |
|
|
| Recruiting | 2 | 120 | Europe | 68Ga-NOTA-AE105 PET/CT | Rigshospitalet, Denmark | Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma, Large Cell Neuroendocrine Carcinoma of the Lung | 04/23 | 10/23 | | |
OCCLURANDOM, NCT02230176: Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II |
|
|
| Recruiting | 2 | 80 | Europe | Sunitinib, 177Lu-DOTA0-Tyr3-Octreotate | Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France, Advanced Accelerator Applications | Pancreatic Neuroendocrine Carcinoma | 10/23 | 10/23 | | |
NCT02493582: The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR |
|
|
| Active, not recruiting | 2 | 400 | RoW | Cytokine-Induced Killer Cells, CIK, Apatinib, YN968D1 | The First People's Hospital of Changzhou | Adenocarcinoma of Lung | 07/30 | 07/33 | | |
NCT03081377: Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in HCC |
|
|
| Recruiting | 1 | 15 | US | Galunisertib 150mg by mouth twice a day, (LY2157299), SBRT | University of Pennsylvania | Hepatocellular Carcinoma | 09/18 | 09/20 | | |
NCT00915993: MRI in Predicting Response to Sunitinib Malate in Patients With Stage IV Kidney Cancer |
|
|
| Recruiting | N/A | 40 | US | sunitinib malate, mutation analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, dynamic contrast-enhanced magnetic resonance imaging | University of Pennsylvania, National Cancer Institute (NCI) | Kidney Cancer | 05/11 | | | |
NCT00655252 / 2007-005460-28: Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy |
|
|
| No Longer Available | N/A | | US, Canada, Europe, RoW | Everolimus | Novartis Pharmaceuticals | Metastatic Renal Cell Cancer | | | | |
|
|
|
NCT01473043: Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment |
|
|
| No Longer Available | N/A | | Canada, RoW | Axitinib, AG-013736 | Pfizer | Renal Cell Carcinoma | 03/14 | 03/14 | | |
NCT02082691: Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma |
|
|
| No Longer Available | N/A | | US | G-202 | Devalingam Mahalingam, GenSpera, Inc. | Hepatocellular Carcinoma | | | | |
NCT00589030: Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery |
|
|
| No Longer Available | N/A | | US | brachytherapy, yttrium Y 90 glass microspheres | City of Hope Medical Center | Liver Cancer | 09/14 | 09/14 | | |
NCT02358018: 68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial |
|
|
| No Longer Available | N/A | | US | 68Ga-DOTATOC PET/CT Scan | Memorial Sloan Kettering Cancer Center | Neuroendocrine Tumors | | | | |
NCT02448056: MiRNA as a Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma |
|
|
| Not yet recruiting | N/A | 150 | RoW | | National Taiwan University Hospital, Far Eastern Memorial Hospital | Carcinoma, Hepatocellular, Marker, Biological | 05/17 | 05/25 | | |
NCT01980732: 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors |
|
|
| No Longer Available | N/A | | US | 68Ga-DOTA TATE | Andrei Iagaru | Carcinoid Tumors, Islet Cell (Pancreatic NET), Other Neuroendocrine Tumors | | | | |
NCT00701168: Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer |
|
|
| No Longer Available | N/A | | US | yttrium Y 90 microspheres (Therasphere®) | Leo W. Jenkins Cancer Center | Carcinoma, Hepatocellular, Neoplasm Metastasis | | | | |
NCT02784158: An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer |
|
|
| No Longer Available | N/A | | US | Brigatinib, AP26113 | Ariad Pharmaceuticals | Non-small Cell Lung Cancer, Lung Cancer, Advanced Malignancies, Carcinoma | | | | |
NCT02131441: Surgical Specification and Efficacy Evaluation of Total Laparoscopic Left Liver Resection |
|
|
| Recruiting | N/A | 2 | RoW | laparoscopic hepatectomy, open liver resection | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Laparoscopic Hepatectomy, Hepatocellular Carcinoma | 08/18 | 08/23 | | |
RHCC:BCLC-A, NCT02678806: Radiotherapy in Hepatocellular Carcinomas After Hepatectomy With Narrow Margin (<1 cm) and / or Microvascular Invasion |
|
|
| Recruiting | N/A | 620 | RoW | Postoperative radiotherapy, Postoperative TACE | Guangxi Medical University | HepatoCellular Carcinoma | 11/18 | 11/22 | | |
NCT02375464: Gallium-68 DOTATOC for Management of Neuroendocrine Tumors |
|
|
| No Longer Available | N/A | | US | Gallium-68 DOTATOC, Gallium-68 (DOTA0-Phe1-Tyr3)octreotide | Northwell Health | Neuroendocrine Tumors | 12/18 | 12/19 | | |
NCT02389699: Comparison of Intra-operative Radiotherapy With Post-operative Radiotherapy for Women With Ductal Carcinoma in Situ |
|
|
| Active, not recruiting | N/A | 74 | RoW | Intraoperative Radiotherapy, Whole breast radiation | Liao Ning | Breast Neoplasms | 06/19 | 06/24 | | |
NCT02389673: Intra-operative Radiotherapy For Women With Ductal Carcinoma in Situ Breast Cancer |
|
|
| Recruiting | N/A | 222 | RoW | Intraoperative Radiotherapy | Liao Ning | Breast Neoplasms | 06/19 | 06/26 | | |
NCT02186925: A Prospective Study of Clinical Factors Affecting Disease Progression and Treatment Results of Patients With Tumors of the Prostate, Bladder and Kidney. |
|
|
| Recruiting | N/A | 1000 | RoW | | Meir Medical Center | Kidney Cancer, Prostate Cancer, Bladder Cancer | 08/19 | 08/25 | | |
NCT02389686: Intra-operative Radiotherapy For Breast Cancer Women After NSM |
|
|
| Recruiting | N/A | 110 | RoW | INTRABEAM (Carl Zeiss, Oberkochen, Germany) | Liao Ning | Breast Neoplasms | 10/19 | 10/24 | | |
| Recruiting | N/A | 150 | RoW | the caudal-to-cranial approach, the medial-to-lateral approach | Guangdong Provincial Hospital of Traditional Chinese Medicine | Ascending Colon Cancer, Ileocaecal Valve Carcinoma, Cancer Flexure Hepatic, Adenocarcinoma of Hepatic Flexure (Diagnosis) | 02/20 | 12/24 | | |
NCT02313688: Length of the Proximal Resection Margin for Siewert-II/Siewert-III Tumors |
|
|
| Recruiting | N/A | 320 | RoW | gastrectomy | West China Hospital | Stomach Neoplasms, Siewert Type II Adenocarcinoma of Esophagogastric Junction, Recurrence, Siewert Type III Adenocarcinoma of Esophagogastric Junction | 12/20 | 12/23 | | |
| Not yet recruiting | N/A | 500 | Europe | D1 gastrectomy, D2 gastrectomy | Italian Research Group for Gastric Cancer | Gastric Cancer, Locally Advanced Malignant Neoplasm, Perioperative/Postoperative Complications | 12/20 | 12/25 | | |
NCT02514434: Usefulness of Non-contrast MagnetIc Resonance imAging Versus Non-Contrast Ultrasonography for surveiLlancE of HepatoCellular Carcinoma [MIRACLE-HCC] |
|
|
| Active, not recruiting | N/A | 416 | RoW | Ultrasonography, non-contrast MRI | Yonsei University | Compensated Liver Cirrhosis | 12/22 | 12/22 | | |
| Active, not recruiting | N/A | 440 | US | iodinated contrast dye, iodinated radiographic dye, motexafin gadolinium, Xcytrin, Eovist-enhanced MRI | American College of Radiology Imaging Network, National Cancer Institute (NCI) | Liver Cancer | 12/23 | 12/23 | | |
NCT02688491: A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment |
|
|
| Not yet recruiting | N/A | 300 | RoW | sunitinib | First Affiliated Hospital, Sun Yat-Sen University, Health Science Center of Xi'an Jiaotong University, Yantai Yuhuangding Hospital, Sun Yat-sen University | Renal Neoplasms, Targeted Molecular Therapy | 07/26 | 07/26 | | |
NCT00574327: Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry |
|
|
| Recruiting | N/A | 3000 | US | | Midwest Biomedical Research Foundation, Kansas City Veteran Affairs Medical Center | Barrett's Esophagus, Gastroesophageal Reflux Disease, Esophageal Adenocarcinoma | 10/28 | 01/29 | | |
NCT01344837: Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer |
|
|
| Not yet recruiting | N/A | 360 | US | Diagnostic Laboratory Biomarker Analysis, Immunohistochemistry Staining Method, Cell/Tissue, Immunohistochemistry, IHC, Immunohistochemistry, Medical Chart Review, Chart Review, Microarray Analysis, gene expression profile, Gene Expression Profiling, Microarray Technology, Microarray-Based Analysis, Study of Socioeconomic and Demographic Variables, Western Blotting, Blotting, Western, WESTERN BLOT | Gynecologic Oncology Group, National Cancer Institute (NCI) | Endometrial Serous Adenocarcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer | 01/00 | | | |